ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Cancer
Lymphoma
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near New York, NY, USA:

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple...

Active, not recruiting
Multiple Myeloma
Procedure: Stem Cell Mobilization
Drug: Bortezomib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Morristown, New Jersey, United States and 7 other locations

in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of dru...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Clarithromycin

Phase 2

Weill Cornell Medicine (WCM)
Weill Cornell Medicine (WCM)

New York, New York, United States

multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: STI-6129

Phase 1, Phase 2

Sorrento Therapeutics
Sorrento Therapeutics

New York, New York, United States and 2 other locations

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

New York, New York, United States and 24 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Hackensack, New Jersey, United States and 48 other locations

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma...

Begins enrollment in 1 month
Relapsed or Refractory Multiple Myeloma
Drug: mRNA-2808

Phase 1, Phase 2

Moderna
Moderna

New York, New York, United States and 9 other locations

study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple...

Enrolling
Multiple Myeloma
Drug: Teclistamab
Drug: Mezigdomide

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 6 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bendamustine
Drug: CC-95266

Phase 1

Juno Therapeutics

New York, New York, United States and 9 other locations

this study will be to assess the efficacy and safety of treating elderly patients with relapsed/refractory multiple myeloma with a...

Enrolling
Multiple Myeloma in Relapse
Drug: Talquetamab
Drug: Daratumumab

Phase 2

Larysa Sanchez

New York, New York, United States

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

New York, New York, United States and 40 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems